What's breaking now, across thousands of outlets.
Drugmakers and investors have ramped up their spending and R&D attention on autoimmune diseases in recent years, with a proliferation of bispecific T cell engagers, various approaches to CAR-T cell therapy and twists on the ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
Deadly synthetic opioids disguised as legitimate painkillers are being sold online across Europe, as counterfeit medicines linked to multiple deaths in the Netherlands expose the dark side of…
Rather than deplete malfunctioning B cells as many other emerging autoimmune drugs do, Ai3Bio’s therapies are designed to eliminate a particular group of T helper cells.
The equity investment comes alongside a deal to test Summit’s ivonescimab alongside potentially many AstraZeneca drugs — but doesn’t hand the pharmaceutical company any ownership rights.
During Donald Trump’s first presidency, American public opinion broadly shifted leftward. But a new study reveals this "liberal rebound" was accompanied by surging emotional hostility between…
Fresenius Kabi will sell biosimilars directly to employers. To accomplish that, the drugmaker is working with Eversana-owned Waltz Health, which runs a marketplace that helps employers shop for better…
Infections caused by viruses, bacterium and parasites caused an estimated 2.3 million new cancer cases in 2024, with low- and middle-income countries bearing most of the burden.
